Literature DB >> 31006600

CRISPR in Parasitology: Not Exactly Cut and Dried!

Jessica M Bryant1, Sebastian Baumgarten2, Lucy Glover3, Sebastian Hutchinson4, Najma Rachidi5.   

Abstract

CRISPR/Cas9 technology has been developing rapidly in the field of parasitology, allowing for the dissection of molecular processes with unprecedented efficiency. Optimization and implementation of a new technology like CRISPR, especially in nonmodel organisms, requires communication and collaboration throughout the field. Recently, a 'CRISPR in Parasitology' symposium was held at the Institut Pasteur Paris, bringing together scientists studying Leishmania, Plasmodium, Trypanosoma, and Anopheles. Here we share technological advances and challenges in using CRISPR/Cas9 in the parasite and vector systems that were discussed. As CRISPR/Cas9 continues to be applied to diverse parasite systems, the community should now focus on improvement and standardization of the technique as well as expanding the CRISPR toolkit to include Cas9 alternatives/derivatives for more advanced applications like genome-wide functional screens.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Anopheles; CRISPR; CRISPRi; Leishmania; Plasmodium; Trypanosoma

Mesh:

Year:  2019        PMID: 31006600     DOI: 10.1016/j.pt.2019.03.004

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  15 in total

Review 1.  Recent advances in genetic manipulation of Cryptosporidium.

Authors:  Sumiti Vinayak
Journal:  Curr Opin Microbiol       Date:  2020-11-05       Impact factor: 7.934

Review 2.  State-of-the-art CRISPR/Cas9 Technology for Genome Editing in Trypanosomatids.

Authors:  Noelia Lander; Miguel A Chiurillo
Journal:  J Eukaryot Microbiol       Date:  2019-07-07       Impact factor: 3.346

Review 3.  Long non-coding RNAs as possible therapeutic targets in protozoa, and in Schistosoma and other helminths.

Authors:  Gilbert O Silveira; Helena S Coelho; Murilo S Amaral; Sergio Verjovski-Almeida
Journal:  Parasitol Res       Date:  2021-12-03       Impact factor: 2.289

Review 4.  Paving the Way: Contributions of Big Data to Apicomplexan and Kinetoplastid Research.

Authors:  Robyn S Kent; Emma M Briggs; Beatrice L Colon; Catalina Alvarez; Sara Silva Pereira; Mariana De Niz
Journal:  Front Cell Infect Microbiol       Date:  2022-06-06       Impact factor: 6.073

5.  Development of a CRISPR/Cas9 system in Entamoeba histolytica: proof of concept.

Authors:  Monica Mendes Kangussu-Marcolino; Pedro Morgado; Dipak Manna; Heather Yee; Upinder Singh
Journal:  Int J Parasitol       Date:  2020-11-29       Impact factor: 3.981

6.  CRISPR-Mediated Transcriptional Repression in Toxoplasma gondii.

Authors:  Benedikt M Markus; Elizabeth A Boydston; Sebastian Lourido
Journal:  mSphere       Date:  2021-10-13       Impact factor: 4.389

7.  Effective Genome Editing in Leishmania (Viannia) braziliensis Stably Expressing Cas9 and T7 RNA Polymerase.

Authors:  Caroline R Espada; José Carlos Quilles; Andreia Albuquerque-Wendt; Mario C Cruz; Tom Beneke; Lucas B Lorenzon; Eva Gluenz; Angela K Cruz; Silvia R B Uliana
Journal:  Front Cell Infect Microbiol       Date:  2021-11-10       Impact factor: 5.293

Review 8.  Next-Generation Technologies and Systems Biology for the Design of Novel Vaccines Against Apicomplexan Parasites.

Authors:  Mariela Luján Tomazic; Virginia Marugan-Hernandez; Anabel Elisa Rodriguez
Journal:  Front Vet Sci       Date:  2022-01-07

9.  Application of CRISPR/Cas9-Based Reverse Genetics in Leishmania braziliensis: Conserved Roles for HSP100 and HSP23.

Authors:  Vanessa Adaui; Constanze Kröber-Boncardo; Christine Brinker; Henner Zirpel; Julie Sellau; Jorge Arévalo; Jean-Claude Dujardin; Joachim Clos
Journal:  Genes (Basel)       Date:  2020-09-30       Impact factor: 4.096

Review 10.  A nuclear enterprise: zooming in on nuclear organization and gene expression control in the African trypanosome.

Authors:  Joana R C Faria
Journal:  Parasitology       Date:  2021-01-07       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.